๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cibus, Inc. (CBUS)
NASDAQ: CBUS ยท Real-Time Price ยท USD
1.230
-0.140 (-10.22%)
Nov 19, 2026, 4:00 PM EST - Market closed

Cibus Earnings Call Transcripts

Fiscal Year 2026

  • Q3 revenue rose YoY and operating expenses fell, while net loss narrowed; cash is expected to fund operations into early Q1 2027, with near-term capital needed. Bio-fragrance and rice advanced, supporting focused commercialization plans.

  • Revenue grew 35% year-over-year, driven by Sustainable Ingredients, while cost discipline reduced operating expenses and net loss. Rice royalty revenue is expected to begin in 2028, with a multi-year ramp to over $200 million annually. Regulatory progress in the EU and Americas supports future launches.

  • EU regulatory changes now treat gene editing as natural breeding, unlocking major markets and accelerating commercialization. Rapid Trait Development System enables faster, non-GMO crop trait delivery, with rice and fragrance products set to drive revenue growth and profitability by 2028-2029.

  • AGM 2026

    The meeting saw the re-election of all nine directors, approval of executive compensation, and auditor ratification. No additional proposals or pertinent shareholder questions were presented. Final voting results will be filed with the SEC.

  • Q1 2026 saw strong commercial progress, cost reductions, and a $37M capital raise, supporting a clear path to 2027 LATAM rice launch and ramping sustainable ingredients revenue. U.S. rice launch is delayed to 2029, but regulatory and partner milestones advance commercialization.

Fiscal Year 2025

  • 2025 marked a transformative year with major regulatory wins, expanded commercial partnerships, and significant cost reductions. The rice and sustainable ingredients programs are advancing toward key revenue milestones, supported by a strengthened cash position and streamlined operations.

  • Commercial traction accelerated with seven RISE agreements and expansion into India, targeting over $200 million in potential annual royalties. Cost reductions improved the cash runway, and initial biofragrance revenues are expected in 2026, with major commercial launches set for 2027 and beyond.

  • The event highlighted advances in gene editing for crop productivity, rapid trait development, and a royalty-based business model targeting global markets. Regulatory progress, especially in Europe, and strong industry partnerships position the company for significant growth in the coming years.

  • Focused execution on rice and biofragrance programs drove Q2 revenue growth and cost reductions, with initial biofragrance revenues expected in late 2025 and major rice trait launches in 2027โ€“2028. Cash runway extends into Q2 2026, supported by a recent public offering and disciplined capital allocation.

  • Gene-edited crop traits are advancing rapidly with global regulatory acceptance, enabling a royalty-based business model targeting major crops. Key traits in rice and canola are set for commercial launch in 2027, with additional disease and herbicide tolerance traits in development.

  • Q1 2025 saw strong commercial and regulatory progress, with revenue up year-over-year and key milestones in rice, canola, and soybean platforms. Cash burn was reduced, but a $21M goodwill impairment led to a higher net loss. Regulatory advances and new partnerships support a positive outlook.

  • The conference highlighted rapid advances in industrialized gene editing for major crops, a favorable global regulatory shift, and a transition from R&D to commercial revenue with significant royalty potential. Recent fundraising, strong field trial data, and key partnerships position the business for scalable growth.

Fiscal Year 2024

Fiscal Year 2023